Gene Solutions在EMSO亚洲披露了AI驱动的癌症血液测试,显示在成像前早期发现和重现检测。 Gene Solutions unveiled AI-driven cancer blood tests at ESMO Asia, showing early detection and recurrence detection ahead of imaging.

Gene Solutions在新加坡举行的2025年EMSO亚洲大会上展示了AI动力液体活性检查和多种工程学的进展,着重介绍了SPOT-MAS,这是对六个亚洲国家涉及12 000多人的现实世界研究中具有高度敏感性和特殊性的多癌症早期检测的血液测试。 Gene Solutions showcased AI-powered liquid biopsy and multi-omics advances at the 2025 ESMO Asia Congress in Singapore, highlighting SPOT-MAS, a blood test for multicancer early detection with high sensitivity and specificity in real-world studies across six Asian countries involving over 12,000 people. K-TRACK ctDNA-MRD检测发现癌症复发时间比成像早14个月,而K-4CARE平台提高了复杂病例的精确度,如未知初级癌症。 The K-TRACK ctDNA-MRD assay detected cancer recurrence up to 14 months earlier than imaging, while the K-4CARE platform improved precision in complex cases like cancer of unknown primary. 该公司在7份摘要中报告了2份最佳海报奖,扩大了在印度、土耳其、台湾、香港和中国内地的存在,并进行了关于早期发现和治疗监测的高级大规模研究,这符合欧洲应急厅关于稳健、公平的AI生物标志准则。 The company reported two Best Poster Awards among seven presented abstracts, expanded its presence across India, Turkey, Taiwan, Hong Kong, and Mainland China, and advanced large-scale studies on early detection and treatment monitoring, aligning with ESMO’s guidelines on robust, fair AI biomarkers.